Nuvectis Pharma, Inc. Net Fee Amt
Nuvectis Pharma, Inc. (NVCT) had Net Fee Amt of $22.81 thousand as of 2026-08-20, per its S-3 filed 2026-08-21.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-21
- 2026-08-20: Net Fee Amt $22.81K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-20 | $22.81K S-3 · filed 2026-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |